| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3362141 | International Journal of Infectious Diseases | 2015 | 4 Pages |
•Thirty-one patients out of 220 subjects developed drug-induced hepatotoxicity.•The results for the CYP3A5 gene were not significant among the investigated groups.•The results for the CYP2B6 gene were significant among the investigated groups.
SummaryObjectivesThe treatment of tuberculosis (TB) remains a challenge owing to the high incidence of drug-induced hepatotoxicity. The aim of this study was to examine the effect of two gene polymorphisms, one in the CYP2B6 (rs3745274) gene and one in the CYP3A5 (rs776746) gene, on the development of hepatotoxicity in patients treated with anti-TB drugs in a Brazilian Amazon population.MethodsTB patients who were treated with anti-TB drugs were examined for hepatotoxicity, an adverse effect that is characterized by liver damage. The genotype frequencies of the CYP2B6 and CYP3A5 genes examined in this study were assessed using RT-PCR.ResultsThirty-one of the 220 subjects (14.1%) included in this study developed drug-induced hepatotoxicity. The result was significant when the TT homozygous mutant of the CYP2B6 gene was analyzed with additional key variables (p = 0.046; odds ratio (OR) 0.063, 95% confidence interval (CI) 0.004–0.955), which may explain the hepatotoxicity results in this study. Using a univariate statistical model to associate the CYP3A5 gene A6986G polymorphism with the examined drugs, the results did not differ between samples from individuals with and without hepatotoxicity (p = 0.176; OR 0.562, 95% CI 0.255–1.238).ConclusionsThe G516T polymorphism in the CYP2B6 gene is a key predictor of the therapeutic response to treatment in TB patients.
